Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease

Published

News published by Insmed Incorporated concerning ARIKAYCE, administered using Lamira®, an optimized eFlow® Technology nebulizer.
 

Read the press release

Back to overview